These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 18536658)

  • 1. What you don't know will hurt you.
    Nat Biotechnol; 2008 Jun; 26(6):589. PubMed ID: 18536658
    [No Abstract]   [Full Text] [Related]  

  • 2. The FDA and safety--beyond the heparin crisis.
    Laurencin CT; Nair L
    Nat Biotechnol; 2008 Jun; 26(6):621-3. PubMed ID: 18536680
    [No Abstract]   [Full Text] [Related]  

  • 3. Canaries, coal mines and the drug supply.
    Leiden JM
    Nat Biotechnol; 2008 Jun; 26(6):624-6. PubMed ID: 18536681
    [No Abstract]   [Full Text] [Related]  

  • 4. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 5. What you should know about FDA-USP Drug Product Problem Reporting Program.
    McGinnis DM
    Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
    [No Abstract]   [Full Text] [Related]  

  • 6. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 7. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 8. Post-marketing strategies for medicines.
    Breckenridge A
    Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract]   [Full Text] [Related]  

  • 9. Equivocal role of micelles in Eprex adverse events.
    Smiell JM
    Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595347
    [No Abstract]   [Full Text] [Related]  

  • 10. Equivocal role of micelles in Eprex adverse events.
    Schellekens H; Crommelin DJ
    Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595346
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA embraces RFID to protect drug supply.
    Young D
    Am J Health Syst Pharm; 2004 Dec; 61(24):2612, 2615. PubMed ID: 15646694
    [No Abstract]   [Full Text] [Related]  

  • 12. What you should know about device recalls.
    OR Manager; 2002 Apr; 18(4):21. PubMed ID: 11962164
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 14. Traditional drug-discovery model ripe for reform.
    Cressey D
    Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796
    [No Abstract]   [Full Text] [Related]  

  • 15. The drug safety system conundrum.
    Tiedt TN
    Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
    [No Abstract]   [Full Text] [Related]  

  • 16. A quiet revolution in lead optimisation services?
    Cavalla D
    Drug Discov Today; 2004 Aug; 9(15):635-6. PubMed ID: 15279844
    [No Abstract]   [Full Text] [Related]  

  • 17. Changes in the business of culture.
    Pissarra Pde N
    Nat Biotechnol; 2004 Nov; 22(11):1355-6. PubMed ID: 15529153
    [No Abstract]   [Full Text] [Related]  

  • 18. The quiet revolution: outsourcing in pharma.
    Crossley R
    Drug Discov Today; 2004 Aug; 9(16):694. PubMed ID: 15341780
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug regulation 2056.
    Bezold C; Peck J
    Food Drug Law J; 2005; 60(2):127-36. PubMed ID: 16097091
    [No Abstract]   [Full Text] [Related]  

  • 20. Biomanufacturing, from bust to boom...to bubble?
    Thiel KA
    Nat Biotechnol; 2004 Nov; 22(11):1365-72. PubMed ID: 15529157
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.